Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited American Depositary Shares
(NY:
TEVA
)
31.74
+0.20 (+0.63%)
Official Closing Price
Updated: 5:00 PM EST, Dec 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries Limited American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
December 24, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026
↗
December 24, 2025
Duquesne Family Office's billionaire boss has jettisoned the faces of the artificial intelligence (AI) revolution in favor of a drugmaker whose shares have rallied 191% since the beginning of 2024.
Via
The Motley Fool
Topics
Artificial Intelligence
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
December 19, 2025
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain...
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
My Top 10 Portfolio Holdings for 2026
↗
December 19, 2025
This combination of growth and value stocks has the tools and intangibles necessary to outperform in the year to come.
Via
The Motley Fool
Topics
Stocks
3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today
↗
December 17, 2025
Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan.
Via
The Motley Fool
Topics
Intellectual Property
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
↗
December 14, 2025
Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.
Via
The Motley Fool
Topics
Intellectual Property
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
December 12, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Releases Q4 2025 Aide Memoire
December 12, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Glenview Capital Management Sells $71 Million of Alight Stake After Stock's 71% Drop
↗
December 09, 2025
Glenview Capital Management reduced its stake in Alight by roughly 16% during the third quarter.
Via
The Motley Fool
Topics
Regulatory Compliance
Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing
↗
December 09, 2025
Glenview Capital Management added to its massive position in Teva Pharmaceuticals stock.
Via
The Motley Fool
Topics
Regulatory Compliance
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
December 09, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
December 03, 2025
The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,...
Via
MarketMinute
Topics
Artificial Intelligence
Death
Intellectual Property
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks
↗
November 30, 2025
Stanley Druckenmiller is considered one of the greatest investors of all time.
Via
The Motley Fool
Topics
Artificial Intelligence
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared
↗
November 27, 2025
Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.
Via
Stocktwits
Topics
ETFs
JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets
↗
November 26, 2025
JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.
Via
Stocktwits
Topics
Economy
Government
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied
↗
November 26, 2025
Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.
Via
Investor's Business Daily
Topics
Economy
Government
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
November 25, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
November 21, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report
↗
November 19, 2025
Jury convicts Done Global founder Ruthia He and former top doctor David Brody in a federal case alleging illegal Adderall distribution through the telehealth platform.
Via
Benzinga
Topics
Law Enforcement
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
November 19, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves
↗
November 14, 2025
Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 11, 2025
Via
Benzinga
Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023
↗
November 11, 2025
Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) darlings and piling into a previously struggling pharmaceutical stock.
Via
The Motley Fool
Topics
Artificial Intelligence
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
↗
November 10, 2025
Via
Benzinga
Price Over Earnings Overview: Teva Pharmaceutical Indus
↗
November 10, 2025
Via
Benzinga
Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio?
↗
November 09, 2025
Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.
Via
Benzinga
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
November 07, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Why Teva Pharmaceutical Stock Rocked the Market Today
↗
November 05, 2025
The company delivered a convincing pair of beats in its third-quarter earnings report.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
↗
November 05, 2025
Via
Benzinga
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
↗
November 05, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.